Safety Alert for TRELLIS Peripheral Infusion System

According to National Institute of Drugs and Food Surveillance (INVIMA), this safety alert involved a device in Colombia that was produced by COVIDIEN IIC || EV3 INC.

What is this?

Alerts provide important information and recommendations about products. Even though an alert has been issued, it does not necessarily mean a product is considered to be unsafe. Safety Alerts, addressed to health workers and users, may include recalls. They can be written by manufacturers, but also by health officials.

Learn more about the data here
  • Type of Event
    Safety alert
  • Event ID
    R1502-74
  • Event Number
    2014DM-0012263
  • Date
    2015-02-18
  • Event Country
  • Event Source
    INVIMA
  • Event Source URL
  • Notes / Alerts
    Colombian data is current through June 2019. All of the data comes from the National Institute of Drugs and Food Surveillance (INVIMA), except for the categories Manufacturer Parent Company and Product Classification.
    The Parent Company and the Product Classification were added by ICIJ.
    The parent company information is based on 2017 public records. The device classification information comes from FDA’s Product Classification by Review Panel, based on matches of recall data from the U.S. and Colombia.
  • Extra notes in the data
  • Reason
    The manufacturer reports that a manufacturing error caused balloon inflation ports to be mislabeled, which may cause the physician using the device to inflate balloons in the wrong order, causing potential formation of blood clots that may be dislodged and mobilized within of the lungs, leading to the generation of possible adverse events on the patient.

Device

  • Model / Serial
    TRELLIS 6 and TRELLIS 8, models BVT608010, BVT608030, BVT612010, BVT612030, CVT808015, CVT808025, || CVT812015, CVT812025, EVT808015, EVT808025, || EVT812015V01 and EVT812025V01, specific lots
  • Product Classification
  • Product Description
    The TRELLIS peripheral infusion system is designed for the controlled and selective infusion of liquids, includingtrolyolitics, inside the peripheral vasculature.
  • Manufacturer

Manufacturer

  • Manufacturer Parent Company (2017)
  • Manufacturer comment
    “If our surveillance systems identify a potential performance issue, our personnel promptly evaluate the problem, including, when appropriate, conducting root cause investigations and internal testing to assess whether the product continues to meet specifications and defined performance criteria,” Medtronic told ICIJ in a statement. “In some cases, based on this evaluation, Medtronic may determine that a recall is necessary.” The company said that it communicates with healthcare providers and/or patients and provide recommendations to address such issues. Medtronic noted that these communications can include letters, emails, calls, press releases, physician notifications and social media postings, as well as informing the FDA and other regulators of the actions.
  • Source
    NIDFSINVIMA